Egerdie, R B <br/><br/>
Responder analysis of the effects of denosumab on bone  mineral density in men receiving androgen deprivation  therapy for prostate cancer.  [electronic resource] 

 -  Prostate cancer and prostatic diseases  Sep 2012 
 - 308-12 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1476-5608 
<br/><br/><label>Standard No.: </label>10.1038/pcan.2012.18  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Aged, 80 and over<br/>Androgen Antagonists--therapeutic use<br/>Antibodies, Monoclonal, Humanized--pharmacology<br/>Antineoplastic Agents, Hormonal--therapeutic use<br/>Bone Density--drug effects<br/>Bone Density Conservation Agents--pharmacology<br/>Denosumab<br/>Humans<br/>Male<br/>Middle Aged<br/>Prostatic Neoplasms--drug therapy<br/>RANK Ligand--antagonists & inhibitors<br/>Treatment Outcome